Anaferon / Materia Medica, EastGate Biotech - LARVOL DELTA

"Por cierto no hablo solo por hablar, eh salido"positivo"3 veces creo una en cada"ola"ni yo ni mis niños ni esposa tenemos "secuelas",por supuesto q no estamos vacunados y no usamos cubrebocas,si reforzamos sistema immunologico, ejercicio, sol, y 0 miedo. Dales anaferon infantil" (@Darksouldf1)

Immunology

Clinical Trial of Efficacy and Safety of Anaferon in the Treatment of Acute Respiratory Viral Infections (clinicaltrials.gov) - P4; N=204; Recruiting; Sponsor: Materia Medica Holding

New P4 trial • Biosimilar

Clinical Trial of Efficacy and Safety of Anaferon for Children Liquid Dosage Form in the Treatment of Acute Upper Respiratory Infections (clinicaltrials.gov) - P3; N=142; Completed; Sponsor: Materia Medica Holding

New P3 trial • Biosimilar • Immunology

The level of natural autoantibodies to IFN-gamma in varicella infections treated with antiviral drug Anaferon for Children: a pilot study. (PubMed, Immunol Lett) - "In the AC group, the NAbs level observed on days 5 and 10 decreased significantly to a level of 154 × 10 U/ml, whereas in the placebo group it continued to rise in a time-dependent manner reaching 229 × 10 U/ml on day 10. Our findings suggest that treatment with AC is characterized by "normalization" of the anti-IFN-γ NAbs levels in patients with varicella infection."

Clinical • Journal • IFNG

The efficacy of anti-viral therapy and serotherapy of tick-borne encephalitis in children (PubMed, Zh Nevrol Psikhiatr Im S S Korsakova) - "In patients of group 1, the period of increase in symptoms was reduced by ~ 4 days, and the duration of impairment of consciousness and pleocytosis in CSF ~ by 5 days, which was accompanied by a faster clearance of the virus in CSF, compared with group 2. In group 1, recovery without neurological deficit was observed in 83.3% (n=70), all patients had no progression of infection. In group 2, 30% of children (n=6) acquired TBEV chronic infection, and in 55% (n=11) there was a neurological deficit without progression. In patients of group 3 with chronic TBEV, the improvement was observed in 86.7% of cases, and complete regression of symptoms occurred in 1 patient, and replication of the virus was arrested in all of them. In group 4, symptoms increased in 72.7%, while virus replication was preserved and atrophic changes in the CNS increased on MRI. Antiviral therapy (ribavirin, IFN-α2 and release of active antibodies to gamma interferon -anaferon children) has the highest..."

Clinical • Journal

The results of a randomized clinical trial of the efficacy of the antibodies-based drug in influenza and acute respiratory viral infections in children (ERS 2019) - "To investigate the efficacy of Anaferon for Children (AC), based on released-active form of antibodies to interferon-gamma, in children with ARVI, i.a. influenza...As a part of ARVI/influenza complex therapy, AC promotes recovery and elimination of influenza A/B viruses from respiratory epithelial cells. The lack of information on influenza vaccination is the limitation of this study."

Clinical

Drug discovery today: no molecules required. (PubMed, BMJ Evid Based Med) - No abstract available.

Journal

Clinical Trial of Anaferon for Children Efficacy in Prevention of Influenza and Other Acute Respiratory Viral Infections in Children During the Peaks of Seasonal Morbidity (clinicaltrials.gov) - P4; N=1036; Completed; Sponsor: Materia Medica Holding; Active, not recruiting ➔ Completed

Clinical • Trial completion

Clinical Trial of Anaferon for Children Efficacy in Prevention of Influenza and Other Acute Respiratory Viral Infections in Children During the Peaks of Seasonal Morbidity (clinicaltrials.gov) - P4; N=1036; Active, not recruiting; Sponsor: Materia Medica Holding; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed

Clinical Trial of Efficacy and Safety of Anaferon in the Treatment of Acute Respiratory Viral Infections (clinicaltrials.gov) - P4; N=204; Completed; Sponsor: Materia Medica Holding; Recruiting ➔ Completed; Trial completion date: Aug 2019 ➔ Mar 2019; Trial primary completion date: Aug 2019 ➔ Mar 2019

Clinical • Trial completion • Trial completion date • Trial primary completion date